May 1 Facebook Live Session on ALS Sponsored by Muscular Dystrophy Association

  • Amyotrophic Lateral Sclerosis
  • Neuromuscular disease

To mark the beginning of amyotrophic lateral sclerosis (ALS) awareness month, the Muscular Dystrophy Association (ALS) is sponsoring a special virtual conversation on Facebook Live about best practices and precautions for people with ALS during the COVID-19 pandemic. The Facebook Live event will feature Dr. Matthew B. Harms and Kristin Stephenson and a live Q&A open to a global ALS audience. The goal of the conversation is to provide the answers to care questions. People living with ALS and related diseases in the neuromuscular disease community (including muscular dystrophy, SMA, Duchenne and related rare diseases) have some of the highest risks for COVID-19 yet are among the most overlooked. This conversation and Q&A aim to bring those concerns to light. 

The Facebook Live will also cover topics related to preparedness, community impact, telemedicine and MDA care and resources. These guidelines will continually be updated on the MDA resource page for COVID-19. Questions may be asked in advance on the @MDAorg Facebook page.
WHEN: The Facebook Live event will occur on Friday, May 1 at 3-3:30 p.m. ET 



Matthew B. Harms, MD: Dr. Harms is MDA’s Medical Consultant on the strategic Chief Medical Advisory Team. He is MDA’s Medical Consultant and Associate Professor of Neurology, Columbia University, and a leading voice in ALS and neuromuscular disease research and care.

Kristin Stephenson, MHA, J.D.: Stephenson is the Executive Vice President, Chief Advocacy & Care Services Officer for Muscular Dystrophy Association. She oversees MDA's Care & Clinical Services Division, which includes MDA's Care Center Network, National Resource Center, and MDA's nationwide Care & Clinical Services field team. She also leads MDA's Public Policy & Advocacy Department

COVID-19 Patient Registry for People with Autoimmune Diseases, Including MS, Launches

Previous News Article

First Participant Received Batoclimab in Phase 1b/2a Trial for Neuromyelitis Optica Spectrum Disorder

Next News Article